CING · Cingulate Inc
United States · RS rating 51 · As of 2026-11-03
| Price | 4.72 USD |
|---|---|
| 1-day change | -6.2% |
| RS rating (overall / 1M / 3M / 12M) | 51 / 54 / 57 / 72 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 32 / 27 / 49 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +29.6% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +59.5% |
| Market cap (USD) | $68.8M |